Cold and flu season boosts demand for Strepsils at Reckitt Benckiser

Consumer products giant Reckitt Benckiser reported decent growth in the first quarter with its Health division performing strongly as a more favourable cold and flu season increased the demand for Strepsils, Mucinex and certain Nurofen products.

Consumer products giant Reckitt Benckiser reported decent growth in the first quarter with its Health division performing strongly as a more favourable cold and flu season increased the demand for Strepsils, Mucinex and certain Nurofen products.

Net revenue tolled £2,517m in the first three months of 2013, up 7.0% at constant currency and 7.0% higher on a like-for-like basis. Excluding Reckitt Benckiser Pharmaceuticals (RBP), growth was 6.0%.

The firm said that it is well-placed to achieved its full-year target for revenue growth of 5-6% at constant exchange (excluding RBP).

Health, which accounts for 27% of revenues, saw sales grow 30% (up 13% on a LFL basis) to £597m as all of its 'powerbrands' registered growth due to strong performances from flu-related brands.

"This was due to higher incidences of cold and flu in the US supported by increased TV and digital BEI initiatives as we leveraged increased cold & flu search volumes."

The Durex brand was also performing well, helped from greater exposure in China and the roll-out of a new product in a number of markets.

The biggest division, Hygiene (46% of revenue), registered 7.0% growth (LFL up 9.0%) driven by strong growth in the Dettol and Lysol brands across both the emerging markets, and Europe and North America.

The Home division (22% of revenue) reported sales of £488m, unchanged on last year on a reported basis (LFL up 2.0%) was a difficult consumer environment weighed on the performance.

RBP saw strong growth of 19%, helped by underlying growth in prescriptions in the US. "As signalled with our 2012 full year numbers, the Q1 2013 reported growth was increased by the sell-in to drug wholesalers of new 4mg and 12mg film dosages, and the tail of the high Medicaid accruals in Q1 2012."

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021
Nuclear power might never be popular – but now looks a good time to invest
Commodities

Nuclear power might never be popular – but now looks a good time to invest

Nuclear power gets a very bad press, but it is the ultimate renewable energy source. Interest in it is perking up again, says John Stepek. Which means…
9 Apr 2021
How to find companies that can thrive in the post-Covid world
Advertisement Feature

How to find companies that can thrive in the post-Covid world

Many sectors of the global economy will return to something resembling pre-pandemic status, but others will take far longer to recover.
8 Apr 2021